Gluetacs Therapeutics Files IND for Molecular Glue Degrading Agent in China
Gluetacs Therapeutics has reported filing an Investigational New Drug (IND) application for its first molecular...
Gluetacs Therapeutics has reported filing an Investigational New Drug (IND) application for its first molecular...
Global Cord Blood Corporation (OTCMKTS: CORBF) has announced that the Grand Court of the Cayman...
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced a licensing agreement with Belgium’s...
Yiming (Beijing) Cell Biotechnology Co., Ltd, also known as Ubrigene, a gene and cell therapy...
The National Medical Products Administration (NMPA) has approved the proton therapy system developed by Shanghai...
China-based Brii Biosciences Limited (HKG: 2137) has published the top-line results from a Phase I...
China’s Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary, Beijing Tide Pharmaceutical Co....
China Resources Pharmaceutical Group Co., Ltd (HKG: 3320) has published its 2022 interim financial report,...
Hangzhou Sciwind Biosciences Co., Ltd has announced a research partnership with SynerK Inc. The collaboration...
China-based ophthalmic therapies developer Arctic Vision has announced the first injection of triamcinolone acetonide suprachoroidal...
China-based Jiangsu Synthgene Biotechnology Co., Ltd has entered into a partnership with compatriot firm Micor&Nano...
ThunderBio Innovation Limited, a specialist in droplet microfluidics and molecular diagnostics based in Zhejiang, has...
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced that it has received approval...
China-based biotech Everest Medicines (HKG: 1952) has announced that it has received approval from the...
US-based Boston Scientific Corporation (NYSE: BSX) has announced the completion of the first surgery using...
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has released its 2022 interim report for...
China’s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHA: 002693) has announced a licensing and supply agreement...
China-based generics firm HEC Pharma has managed to overturn a previous final decision in a...
Italy-based Nerviano Medical Sciences S.r.l. (NMS), which is 90% owned by Chinese investment fund SARI...
The Chief Medical Officer (CMO) of US-based Moderna Inc. (NASDAQ: MRNA), Paul Burton, has been...